Lutathera Articles
Lutathera first MNM theragnostic drug, enters Ph III in cancer patients with midgut carcinoid
20 September 2012
Showing 1-2 of 2 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
